Join Growin Stock Community!

泰福-KY6541.TW Overview

TW StockBiotech. & Medical
(No presentation for 6541)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

泰福-KY（6541）Overall Performance

泰福-KY（6541）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

泰福-KY（6541） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

泰福-KY（6541）Key Information

泰福-KY（6541）Profile

Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar in Taiwan and the United States. The company focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. Its products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

泰福-KY（6541）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.13
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
56.16
PB Ratio
2.10
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-86.98%
Net Margin
-603.94%
Revenue Growth (YoY)
448.96%
Profit Growth (YoY)
-1902.29%
3-Year Revenue Growth
146.88%
3-Year Profit Growth
155.92%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.13
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
56.16
PB Ratio
2.10
Price-to-FCF
-
Gross Margin
-86.98%
Net Margin
-603.94%
Revenue Growth (YoY)
448.96%
Profit Growth (YoY)
-1902.29%
3-Year Revenue Growth
146.88%
3-Year Profit Growth
155.92%
6541.TW logo

6541

泰福-KY

47.70D

-1.89%

(-0.02)

  • When is 6541's latest earnings report released?

    The most recent financial report for 泰福-KY (6541) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6541's short-term business performance and financial health. For the latest updates on 6541's earnings releases, visit this page regularly.

  • What is the operating profit of 6541?

    According to the latest financial report, 泰福-KY (6541) reported an Operating Profit of -286.29M with an Operating Margin of -228.42% this period, representing a growth of 2.73% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6541's revenue growth?

    In the latest financial report, 泰福-KY (6541) announced revenue of 125.34M, with a Year-Over-Year growth rate of 989.6%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6541 have?

    At the end of the period, 泰福-KY (6541) held Total Cash and Cash Equivalents of 1.39B, accounting for 0.17 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6541 go with three margins increasing?

    In the latest report, 泰福-KY (6541) did not achieve the “three margins increasing” benchmark, with a gross margin of -129.5%%, operating margin of -228.42%%, and net margin of -218.21%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6541's profit trajectory and future growth potential.

  • Is 6541's EPS continuing to grow?

    According to the past four quarterly reports, 泰福-KY (6541)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.08. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6541?

    泰福-KY (6541)'s Free Cash Flow (FCF) for the period is -1.04B, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 2,310.62% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.